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Results from indirect ELISAs using synthetic peptides of various length that represent segments of the ectodomain of the
envelope glycoprotein, VP-3P, of lactate dehydrogenase-elevating virus (LDV) showed that the primary neutralization epitope
of LDV is located in a short linear hydrophilic segment in the center of the ectodomain. The epitope becomes slightly altered
by amino acid substitutions in the ectodomain and inactivation of virions by various treatments. Neutralizing anti-VP-3P
antibodies (Abs) to the epitope interact with the synthetic peptides only if they possess a certain conformation. When the
peptides were immobilized on ELISA plates, neutralizing mAbs elicited to inactivated LDV and neutralizing Abs from infected
mice bound best to the peptides that consisted of the full-length, 30-amino-acid-long ectodomain. The Abs bound poorly, if
at all, to most of the shorter peptides when immobilized, whether truncated at the N- or C-end, but when in solution the same
peptides strongly inhibited the binding of the Abs to immobilized full-length peptides. Thus, a conformation of the epitope
required for Ab binding and (or) its steric accessibility were lost upon immobilization of the shorter peptides on ELISA plates.
Abs raised in mice to peptide–bovine serum albumin conjugates reacted only with immobilized peptides in the indirect ELISA
and failed to neutralize LDV. The neutralization epitope of the common LDV quasispecies, LDV-P and LDV-vx, is flanked by
N-glycans that block the immunogenicity of the epitope and the neutralization of these LDVs. Abs to a second weakly
immunogenic and probably discontinuous epitope appear in LDV infected mice about 1 month postinfection. © 2001 Academic
Press
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1INTRODUCTION
The mechanism of neutralization of viruses by antibod-
ies (Abs) is generally incompletely understood as are the
structures of the viral epitopes recognized by the neu-
tralizing Abs (Flint et al., 2000; van Regenmortel, 1998;
Whitton and Oldstone, 1996; Parren and Burton, 2001).
The mouse arterivirus lactate dehydrogenase-elevating
virus (LDV) provides a unique model for addressing
these questions since (1) the virus seems to possess
only a single neutralization epitope that is located on the
short (about 30 amino acids long) ectodomain of the
primary envelope glycoprotein, VP-3P (Li et al., 1998); (2)
a number of LDV variants with amino acid differences in
their VP-3P ectodomains have been isolated (Chen et al.,
2000; Plagemann et al., 1999); and (3) batteries of neu-
tralizing mAbs that react with VP-3P have been gener-
ated in two laboratories (Coutelier et al., 1986; Coutelier
and van Snick, 1988; Harty and Plagemann, 1988). Fur-
thermore, linear synthetic peptides consisting of the 30-
amino-acid-long VP-3P ectodomains of some LDV qua-
sispecies have been shown to strongly bind in an indi-
rect ELISA all neutralizing monoclonal Abs (mAbs) that
have been examined as well as antibodies from acutely
and persistently infected mice (Li et al., 1998; Plagemann
et al., 1999).1 To whom reprint requests should be addressed.
11Two classes of LDV quasispecies have been identi-
fied, the common LDV-P and LDV-vx and the neuropatho-
genic laboratory mutants, LDV-C and LDV-v (Chen and
Plagemann, 1997; Chen et al., 1997, 1998). These four
LDVs have been cloned by repeated end-point dilution in
mice from LDVs (LDV-PLA, LDV-C-BR, and LDV-VIR) orig-
inally isolated from mice carrying different transplantable
tumors and found to be mixtures of two or three of these
LDV quasispecies. The VP-3P ectodomains of LDV-P and
LDV-vx contain three large N-glycans (Faaberg and
Plagemann, 1995; Faaberg et al., 1995; see P3 and P6 in
Table 1) that impede the immunogenicity of the neutral-
ization epitope contained in the ectodomain and render
these LDVs highly resistant to in vivo Ab neutralization
(Chen et al., 1999, 2000; Plagemann et al., 1999). In
contrast, the VP-3P ectodomains of LDV-C and LDV-v
lack the two N-terminal N-glycans (see P5 in Table 1).
This allows these LDVs to cytocidally infect the anterior
horn neurons of C58 and AKR mice but incidentally
renders the neutralization epitope on the VP-3P ectodo-
main highly immunogenic and the virions susceptible to
in vivo Ab neutralization (Chen et al., 1998, 1999, 2000).
europathogenic LDV-v has been found to be a genetic
ecombinant of the nonneuropathogenic LDV-vx that has
pecifically acquired the VP-3P ectodomain of LDV-C and
hereby the phenotypic properties of this LDV (Li et al.,
999; Plagemann et al., 2001).In order to further assess the structure and specificity
0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
6
a LDV V
98).
1
1
1
1
C
12 PETER G. W. PLAGEMANNof the LDV neutralization epitope, and the reasons for the
differences in immunogenicity of the epitope and in sen-
sitivity to Ab neutralization between the two classes of
LDV, I have now expanded our repertoire of VP-3P
ectodomain-specific peptides (Table 1) and have exam-
ined by indirect ELISA the binding of the neutralizing
mAbs and Abs from mice infected with various cloned
LDV quasispecies to these peptides. I have also exam-
ined to what extent the VP-3P ectodomain-specific pep-
tides inhibit in solution the binding of the anti-LDV Abs to
selected immobilized peptides. In addition, I have gen-
erated antibodies to peptides containing the neutraliza-
tion epitope and examined their ability to neutralize LDV.
RESULTS
Epitope specificity of neutralizing anti-LDV mAbs
We have demonstrated previously that the neutralizing
mAbs raised to a mixture of formalin-inactivated LDV-P
T
Synthetic Pep
Synthetic
peptide
LDV
specific
30 35
P1 P C L S T E N A C A A G N S
P3 P A C A A G N S S
P4 None A V A A D N S S
P5 C/v A C V A G D S S
P6 vx/ab A C G A S N S S
P7 P N A C A A G N S S
P8 P A C A A G N S S
P9 C/v A G D S S
P10 P N S S T
P11 C/v S S T
P12 P S S T
P13 P S S T
a Amino acids 1 to about 27 of the ORF5 protein represent the signa
1 (Faaberg and Plagemann, 1995). Potential N-glycosylation sites are
re underlined. P4 possesses amino acid differences not found in any
b LDV-a is another nonneuropathogenic LDV variant (Chen et al., 19
25
T
Neutralizing A
mAba Isotype
59-7
59-12
59-18
59-19
IgG2a
IgG2b
IgG2a
IgG1
BALB/C mouse immunized with formal
B6503 E7b
B6501 A4
B6505 H9
IgG2a
IgG2a
IgG2a
129/Sv mouse immunized with UV-ligh
Coutelier personal communication)
3904 H12 IgG3 2-month LDV-RILc-infected BALB/c mou
communication)
a Immunoblotting has shown that all mAbs react specifically with VP
b
&
&For simplicity, these mAbs are referred to in the text as E7, A4, H9, and H
c LDV-PLA and LDV-RIL were found to be mixtures of LDV-P and LDV-vx (Cand LDV-vx (LDV-PLA), 159-7, 12, 18, and 19 (see Table 2)
reacted strongly and about equally in an indirect ELISA
with synthetic peptides consisting of the 30-amino-acid-
long ectodomains of LDV-P, LDV-C/v, and LDV-vx/a, P3,
P5, and P6, respectively (see Table 1), whereas the
nonneutralizing anti-VP-3P mAbs from this battery did not
bind to these peptides (Li et al., 1998). The neutralizing
mAbs reacted only weakly with P4 containing 4-amino-
acid differences not found in any LDV or the N-terminal
short peptide P1 (see Table 1). Similarly four other neu-
tralizing anti-VP-3P mAbs generated in another labora-
tory (see Table 2) reacted with P3, but poorly with P4 (Li
et al., 1998).
I have now compared the reaction of the eight neu-
tralizing mAbs (Table 2) with the full-length peptides and
various additional peptides having truncated N- or C-
termini (Table 1). The results were very similar for the
four mAbs in each set of neutralizing mAbs, whether the
o LDV VP-3P
ino acid sequencea
45 50 55 60
N L I Y N L T L C E L N V T G F Q Q H F
N L T S N L T L C E L N V T G F Q Q H F
N L I Y T S T L C E L N V T G F Q Q H F
N L I K N L T L C E L N V T G F Q Q H F
N L I Y N L T L C E L
N L I Y N L
N L I Y T S T L C E L N V
N L I Y N L T L C E L N V T G F
N L I Y T S T L C E L N V T G F
N L I Y N L T L C E L N V T G F Q Q
N L I Y
de, and the first transmembrane segment begins at about amino acid
face lettering and amino acids that diverge from the LDV-P sequence
P-3P sequence.
VP-3P mAbs
Origin
ivated LDV-PLAc (Harty and Plagemann, 1988)
d LDV-RILc (Coutelier et al., 1986; Coutelier and van Snick, 1988;
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13NEUTRALIZATION EPITOPE OF MOUSE LDVisotype of the mAbs was IgG2a, IgG2b, IgG3, or IgG1, but
the reaction patterns were not identical. A typical binding
pattern is presented for one mAb in Fig. 1 and for easier
T
Summary of Efficiencies of Binding of Various Anti
VP-3P
peptide
Specific
for LDV
mAb
159-7, 12, 18, 19 A4, E7, H9
P1 P 2 2
P3 P 1111 1111
P4 None 1/2 2
P5 C/v 1111 111
P6 vx/a 111 111
P7 P 11 111
P8 P 11 111
P9 C/v 1 1/2
P10 P 1/2 1/2
P11 C/v 2 2
P12 P 1/2 1
a 1111, 111, 11, 1 denote decreasing binding to peptide rela
the linear part of the Ab binding curve was displaced by 1–2, 2–4, or 4–
little specific binding; 2, no significant binding, i.e., comparable to tha
b Summary of results from at least five individual FVB or C57BL/6 mi
time in days) with the stated LDV quasispecies. Because of the higher
with LDV-P or LDV-vx (Fig. 2), more alkaline phosphatase-conjugated an
FIG. 1. Binding of neutralizing mAb B6505 H9 to peptides P3 to P12
as measured by indirect ELISA. All data were obtained in a single
ELISA, which was conducted as described under Materials and Meth-
ods using the indicated peptides.former than the latter so that the alkaline phosphatase reaction rates differed g
plates at 25, 40, and 60 min for assessing the binding of Abs from LDV-C/LDcomparison the consensus results for each set of mAbs
are summarized in Table 3. The results confirm that the
mAbs reacted well with P3, P5, and P6, which encom-
pass the amino acids present in the VP-3P ectodomains
of all currently known LDV quasispecies, including those
of four LDVs isolated from wild house mice (Li et al.,
2000). As found previously, all the neutralizing mAbs
reacted very little, if at all, with P4 with four amino acid
differences not found in any LDV. Significant binding was
also observed to P7 and P8 in which the C-terminal end
of the ectodomain was truncated (Fig. 1 and Table 3), but
the mAbs bound poorly, if at all, to the peptides in which
the N-terminal end was further truncated (P9–12).
The reactions of the sets of neutralizing mAbs with the
various peptides differed slightly. One difference was
that mAbs A4, E7, H9, and H12 reacted slightly better with
P3 than with P5 and that the mAbs A4, E7, and H9
reacted better with P8 than the other mAbs (Table 3). In
addition, mAb H12, but not mAbs A4, E7, and H9, reacted
about equally with P3 and P6, while reacting less well
with P7 and P8 than the latter.
Time courses of generation of epitope-specific Abs in
infected mice
For comparing the peptide binding specificity of the
Abs generated in infected mice, plasma must be ob-
tained from these mice at a time when sufficient Abs
have been generated to allow such comparison. Earlier
studies had shown that high levels of Abs that bind to
peptides P3 and P5 are generated very rapidly in LDV-C
and LDV-v infected mice, reaching maximum levels at 3
P-3P Abs to Peptides of the Ectodomain of VP-3Pa
IMP-LDVb
2
C
(T40–T80)
v
(T40–T80)
vx
(T50–T70)
P
(T50–T70)
2 2 2 2
1 11 111 1111 1111
11 11 11 11
1 1111 1111 111 111
1 11 11 1111 111
1 11 11 1
1/2 1/2 1/2 2
11 11 1/2 2
2 1/2 2 2
2 2 2 2
2 1/2 1/2 2
that exhibiting maximum binding 1111; 111, 11, 1 indicate that
ld dilutions, respectively, toward the Y-axis (e.g., see Fig. 1). 1/2, very
rmal mouse plasma.
se plasma (IMP) was obtained during the indicated time range p.i. (T,
of Abs in the plasma of the mice infected with LDV-C and LDV-v than
se IgG bound to the wells containing the same plasma dilutions of theABLE 3
-LDV V
H1
2
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1/2
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11
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2
2
2
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14 PETER G. W. PLAGEMANNto 4 weeks postinfection (p.i.), whereas the generation of
such Abs was very slow and inefficient in mice infected
with a mixture of LDV-P and LDV-vx (Plagemann et al.,
999). I have now directly compared the time courses of
eneration of peptide binding Abs in mice infected with
ach of the four cloned LDV quasispecies. Figures 2A
nd 2B compare representative time courses of the gen-
ration of P3/P5 binding Abs in LDV-C, LDV-v, LDV-P, and
DV-vx infected mice as determined under the same
xperimental conditions. Comparative results were ob-
ained with at least five mice for each LDV quasispecies.
he results illustrate the rapidity and high magnitude of
eneration of P3/P5 binding Abs in LDV-C and LDV-v
nfected mice, as compared to the slow formation and
uch lower titers of such Abs in LDV-P and LDV-vx
nfected mice. The generation of these Abs was espe-
ially inefficient in LDV-P infected mice, much more so
han in LDV-vx infected mice (Figs. 2A and 2B). Further-
ore, it became apparent that the Abs generated in
DV-C and LDV-v infected mice always bound more ef-
iciently to P5 than P3, whereas the opposite was the
ase for the Abs formed in LDV-P and LDV-vx infected
ice (Figs. 2A and 2B).
pitope specificity of peptide binding Abs generated
uring acute infection with various LDV quasispecies
I have compared in a single ELISA the binding of Abs
FIG. 2. Time courses of formation of P3 and P5 peptide binding Abs
in LDV-C and LDV-P (A) and LDV-v and LDV-vx (B) infected mice.
Plasma samples obtained at the indicated times p.i. (5 T in days) were
ssayed for peptide binding by indirect ELISA as in Fig. 1. The data in
and B were obtained in single ELISAs under identical conditions, but
nly the A405 values for the 1:200 plasma dilutions are plotted.n the plasma of two mice persistently infected with eachof the four LDV quasispecies to P3–P12. Similar patterns
were observed for the duplicate mice and for plasma
samples from at least two additional mice of each qua-
sispecies in other independent experiments. The con-
sensus patterns are summarized in Table 3 and clearly
indicated Ab binding patterns that were quasispecies
specific. First, as predicted by the data in Figs. 2A and
2B, the Abs from LDV-C and LDV-v infected mice bound
best to the LDV-C/v-specific peptide P5, whereas the Abs
from LDV-P and LDV-vx infected mice bound best to the
LDV-P-specific peptide P3. Second, the Abs from LDV-C
and LDV-v infected mice bound considerably to the LDV-
C/v-specific peptide P9, whereas the Abs from LDV-P
and LDV-vx infected mice, like the neutralizing mAbs,
bound to this peptide poorly, if at all. In addition, Abs from
LDV-v infected mice bound almost as well to P3 as to P5,
whereas this was never the case for Abs from LDV-C
infected mice. This was surprising, since the VP-3P
ectodomains of LDV-C and LDV-v are identical (Table 1).
This difference suggests that additional factors may play
a role in determining the specificity of the Abs that are
generated in the infected mice.
Inhibition of the binding of Abs to immobilized
peptides P5 and P6 by VP-3P ectodomain
peptides in solution
The finding that the neutralizing mAbs and the Abs
from infected mice bound only inefficiently, if at all, to the
shorter VP-3P ectodomain peptides (Table 3) was unex-
pected since some of them must encompass the neu-
tralizing epitope, if it is a continuous one. This failure
could have been due to lack of binding of the shorter
peptides to the solid phase of the ELISA wells, but this
seems unlikely since peptides of similar size have been
used successfully in indirect ELISAs (van Regenmortel,
1998) and most of our peptides are quite hydrophobic
and were used at relatively high concentrations (up to 5
mg/well). A more likely possibility that could explain this
failure is that the epitope in the longer peptides pos-
sesses some conformation required for the binding of
the Abs and that this conformation is lost or that the
epitope becomes sterically hindered during immobiliza-
tion of the shorter peptides on the ELISA plates. I have
examined this possibility by determining to what extent
dilutions of VP-3P ectodomain peptides P1–P12 inhibit in
solution the binding of the Abs to peptides P5 and P6 that
were immobilized on the ELISA plates. For the assay I
employed the highest dilution of a test Ab that did not
saturate the plate-bound epitope while achieving close
to maximum binding to the immobilized peptides as
estimated from the indirect ELISA results (see Fig. 1).
Binding competition was quantified by estimating the
peptide concentrations that inhibited Ab binding to im-
mobilized P5 or P6 by 50% (IC50). The strategy is illus-
trated by the data in Fig. 3 for mAbs 159-18 and 159-19.
Mean IC50 values calculated from two or more determi-
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15NEUTRALIZATION EPITOPE OF MOUSE LDVnations are recorded in Table 4. All peptides tested,
except the N-terminal P1 and the mutant P4, inhibited in
solution the binding of the neutralizing mAbs to immobi-
lized P5 (Table 4) and similarly to immobilized P6 (data
FIG. 3. Inhibition by peptides P5, P9, and P13 of the binding of mAbs
159-18 and 159-19 to immobilized peptide P5. ELISA plates coated with
P5 (2 mg/well) and then incubated with blocking solution were further
ncubated with mixtures of 50 ml of PBS or twofold dilutions of the
ndicated peptides in PBS and 50 ml of a 1:20,000 dilution of mAb 159-18
r a 1:10,000 dilution of mAb 159-19 in PBS per well for 1.5 h at 37°C.
he plates were then incubated with alkaline phosphatase-conjugated
nti-mouse IgG and finally with substrate. The broken line indicates
0% of mAb binding in the absence of competing peptides.
T
Summary of Inhibition of Binding of Various Anti-LDV
Binding
Ab
IC
P1 P3 P4 P5 P6
MAb 159-18/19 Nb 2.5 N 6 5
H12 N 10 N 10 10
H9/A4 N 3.5 N 4 4
IMP LDV-P N 3.5 20 5 7
LDV-vx N 5 20 5 5
LDV-C N 10 N 5 $40
LDV-v N 20 N 10 $40
a ELISA plates coated with P5 or P6 (1 mg/well) were incubated with
f the indicated competing peptides (20 or 10 to 0.6 or 0.3 mg/well) an
mAb H12; 1:1000 of mAbs A4 and H9; 1:500 of plasma from 6- to 7-we
infected mice; or 1:50 of plasma from 7- to 8-week LDV-infected mic
conjugated anti-mouse IgG and substrate. The presented IC50 values r
the test Ab to immobilized P5 or P6 by 50% (e.g., see Fig. 3) and are means
b N, no significant competition observed in the test range of concentrationsnot shown). That the binding competition by these pep-
tides was specific was indicated by the failure of P1 and
P4 to compete.
However, the degree of inhibition differed for various
peptides and different mAbs. For example, P11 strongly
inhibited the binding of mAbs 159-18/19 and H9/A4 to
immobilized P5 and P6, whereas P11 inhibited only
weakly the binding of mAb H12 (Table 4). The patterns of
inhibition of the binding of the mAbs to immobilized P5
and P6 by the truncated peptides P7 to P12 in solution
allowed defining the segment in the VP-3P ectodomain
that was recognized by these mAbs, namely, a short
segment in the center of the ectodomain, the N-terminal
end of which is highly hydrophilic (Fig. 4). To verify this
conclusion and to further define the epitope recognized
by these mAbs I obtained an 8-amino-acid-long peptide
(P13) consisting of the hydrophilic portion of the VP-3P
ectodomain that is identical for all LDV quasispecies
(Fig. 4) and determined its effect on the binding of the
various neutralizing mAbs to immobilized P5 and P6.
Indeed, P13 strongly inhibited the binding of mAbs
159-18 and 159-19 and of mAb H12 to P5 (Table 4) and P6
(data not shown). In contrast, P13 had no effect on the
binding of mAb A4 and H9, whereas all other truncated
peptides (P7–P12) significantly inhibited the binding of
these mAbs to P5 (Table 4).
The binding of the plasma Abs from mice infected with
the two classes of LDV to immobilized P5 and P6 was
also inhibited by the shorter peptides in solution but the
patterns of inhibition differed for Abs from LDV-C and
LDV-v infected mice, on the one hand, and LDV-P and
LDV-vx infected mice, on the other hand. Most important
was the finding that P13 inhibited the binding of the Abs
from LDV-P and LDV-vx infected mice, but affected little,
if at all, the binding of Abs from LDV-C and LDV-v infected
mice (Table 4). The results indicate that peptide P13
bs to Immobilized P5 by VP-3P Peptides in Solutiona
ell) of competing peptide
P8 P9 P10 P11 P12 P13
2 2 ,0.5 2 1 4 1.5
0 10 3 5 $30 10 5
6 2 4 3 1 3 N
7 3.5 2 3.5 8 $40 0.5
5 5 1 5 5 10 0.5
0 N ,0.5 12 10 12 $40
0 N 1 6 10 $40 N
g solution and then with mixtures of 50 ml of PBS or twofold dilutions
of test Ab (1:20,000 of mAb 159-18; 1:10,000 of mAb 159-19; 1:5000 of
-C or LDV-v infected mice; 1:100 of plasma from 7- to 8-week LDV-vx
plates were then sequentially incubated with alkaline phosphatase-
nt the concentration of competing peptide that inhibited the binding ofABLE 4
VP-3P A
50 (mg/w
P7
1
$4
$4
blockin
d 50 ml
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16 PETER G. W. PLAGEMANNencompasses the epitope in the VP-3P ectodomain that
is recognized by mAbs 159-18, -19, and H12 and Abs
generated in LDV-P and LDV-vx infected mice at a low
level, but that the epitope(s) recognized by mAbs A4 and
H9 and the Abs generated in LDV-C and LDV-v infected
mice seems to differ slightly (see Discussion).
Relationship between peptide binding Abs and Abs
that neutralize the infectivity of LDV in vitro
and in vivo
There exists a clear correlation between the ability of
the two sets of mAbs to neutralize the infectivity of all
four LDV quasispecies in vitro and of LDV-C/LDV-v in vivo
and their binding to the VP-3P ectodomain peptides in an
indirect ELISA (Li et al., 1998; Chen et al., 1999).
The same properties pertain to the VP-3P ectodomain-
pecific peptide binding Abs that are rapidly generated
n LDV-C and LDV-v infected mice (see Fig. 2). Their
ppearance correlated with the formation of Abs that
eutralized LDV-C and LDV-v in vitro and in vivo (Fig. 5A).
Effective in vivo neutralization was indicated by the rapid
suppression of LDV-C and LDV-v viremia in infected mice
that correlated with the appearance of Abs that neutral-
ized these LDVs in vitro (Fig. 5A) as well as by the finding
that LDV-C and LDV-v replication is not suppressed in
SCID, nude, or B-cell-deficient mice or mice that have
been tolerized by infection as newborns (Chen et al.,
1999; Rowland et al., 1994). In mice incapable of gener-
ating anti-LDV Abs, LDV-C and LDV-v establish high
viremic persistent infections just like LDV-P and LDV-vx
(Chen et al., 1999; and unpublished data; see Fig. 5B).
In contrast, though the mAbs neutralize LDV-P/LDV-vx
in vitro, they have no effect on the replication of these
LDVs in mice (Harty and Plagemann, 1988) and the pep-
tide binding Abs generated early in LDV-C/LDV-v infected
mice that effectively neutralize these LDVs neutralize
FIG. 4. Hydrophobic moment analysis according to Eisenberg et al. (1
f peptides P8 to P13. The N-glycosylation sites are shown by boldfacLDV-P/LDV-vx neither in vitro or in vivo (Chen et al., 1999).arlier studies have shown that Abs that neutralize LDV
n vitro become generated in mice infected with the
riginal isolates of LDV, LDV-PLA, LDV-ROW, LDV-NOT,
nd LDV-RIL (all of which were found to be mixtures of
DV-P and LDV-vx; Chen and Plagemann, 1997), begin-
the postulated ectodomains of VP-3P of LDV-P and LDV-C and outlines
rs.
FIG. 5. Time courses of viremia and of the formation of Abs that
neutralize LDV-C/v in vitro in mice infected with LDV-C or LDV-v (A) or
cloned LDV-P (B). The data in A are combined from seven groups of two
FVB or C57BL/6 mice monitored in independent experiments (also see
Chen et al., 1999; Plagemann et al., 1999). The data in B are for plasma
pooled from two FVB mice. In each case, plasma was obtained at the
indicated time p.i. and assayed for infectious LDV by an end-point
dilution assay in mice (E-E) and for in vitro neutralization of LDV-C or
LDV-v (F-F) and selected samples were analyzed by RT-PCR using
quasispecies-specific primers to confirm the presence of the individual
quasispecies used for infection.
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17NEUTRALIZATION EPITOPE OF MOUSE LDVning about 1 month p.i., but only at a low level and
without affecting viremia (Rowson and Mahy, 1975;
Plagemann, 1996). I have now confirmed these results
using biologically cloned LDV-P. Abs that neutralized
LDV-C (and LDV-P) in vitro became generated beginning
t about 1 month p.i. (Fig. 5B), and, although these Abs
ere effective at neutralizing these LDVs in vitro, their
ppearance had no effect on LDV-P viremia (Fig. 5B).
ore importantly, there was no correlation between the
ime courses and levels of generation of Abs that neu-
ralized LDV in vitro and those that bound to the various
P-3P ectodomain-specific peptides (cf. Figs. 2A and 5B).
n fact, the generation of in vitro neutralizing Abs oc-
urred largely in the absence of formation of peptide
inding Abs. Thus most of the late Abs that neutralize
DV-P in vitro seem to bind to an epitope distinct from the
inear VP-3P ectodomain epitope, more likely a discon-
inuous epitope (see below). Abs to the same or a similar
pitope also seem to become generated in LDV-C and
DV-v infected mice at about 1 month p.i. since at this
ime Abs appear that neutralize LDV-P and LDV-vx in vitro
Chen et al., 1999).
roperties of anti-peptide Abs
I have immunized mice with the LDV-P-specific P3
eptide and the LDV-C/v-specific P5 peptide that were
onjugated via their Cys residue (see Table 1) to bovine
erum albumin (BSA). The mice developed very high
iters of Abs (1:25,000; data not shown) that bound in the
ndirect ELISA to both immobilized P3 and P5, but almost
s well to the mutated P4. The anti-peptide Abs also
ound in an LDV quasispecies-specific manner to the
runcated peptides that are not recognized in the indirect
LISA by the neutralizing mAbs or Abs from infected
ice. The anti-P3-BSA Abs bound significantly to the
DV-P-specific peptides P7, P10, and P12, whereas the
nti-P5-BSA Abs bound to the LDV-C/v-specific P9 pep-
ide. Furthermore, none of the peptides, except P5, com-
eted in solution with the binding of either the anti-P3-
SA or the anti-P5-BSA Abs (at a 1:5000 dilution) to
mmobilized P5 (data not shown). The Abs also lacked
eutralizing activity. The replication of LDV-C and LDV-P
as the same in the peptide-immunized mice as in
onimmunized mice and the Abs failed to neutralize
hese LDVs in vitro (data not shown). Together these
esults indicate that the anti-peptide Abs recognize de-
atured forms of the LDV-P and LDV-C/v neutralizing
pitopes and that only Abs to the native epitopes are
eutralizing.
DISCUSSION
Altogether, my results indicate that the neutralizing
Abs and the peptide binding Abs generated at a low
evel in LDV-P and LDV-vx infected mice recognize a
inear epitope in an 8-amino-acid-long segment (P13)
ocated in the hydrophilic center of the VP-3P ectodo-ain (Fig. 4). This location of the neutralization epitope
ow explains why the N-terminal and the middle N-
lycans on the VP-3P ectodomain are those that impair
he immunogenicity of the epitope and are responsible
or the resistance of LDV-P and LDV-vx to Ab neutraliza-
ion. They are flanking the neutralization epitope (Fig. 4)
nd their loss, as in LDV-C and LDV-v, is sufficient to
ender the epitope highly immunogenic (Figs. 2A and 2B)
nd the virus sensitive to Ab neutralization (Fig. 5A). Also,
eutralization escape mutants of LDV-C and LDV-v have
een shown to have regained the middle N-glycosylation
ite and an N-terminal N-glycosylation site (Chen et al.,
000). The C-terminal N-glycan (see Fig. 4) does not
eem to have any effect on the immunogenicity of the
pitope because it is located about 8 residues down-
tream of it and passed the 49Cys residue thought to form
the S-S bond that links the ectodomain of VP-3P to the
even shorter (about 11 amino acids long) ectodomain of
the M protein (Faaberg et al., 1995). This N-glycosylation
site is preserved in all LDV isolates whether sensitive or
resistant to the humoral immune response and also on
the ectodomains of all isolates of the related arterivirus,
porcine reproductive and respiratory syndrome virus
(Chen et al., 2000), and thus probably plays some other
vital function in virus replication. On the other hand, all
three N-glycans may participate in the polyclonal activa-
tion of B cells caused specifically by LDV-P/LDV-vx in-
fection (Plagemann et al., 2000). The low immunogenicity
of the linear neutralization epitope of LDV-P and LDV-vx
may explain why neutralizing Abs became elicited in a
rabbit only after numerous injections of semipurified
LDV-P/LDV-vx (Cafruny and Plagemann, 1982) recogniz-
ing another low-immunogenicity epitope on VP-3P (the
Abs do not bind to any of the synthetic peptides; unpub-
lished data). The low immunogenicity of the neutraliza-
tion epitope of LDV-P and LDV-vx is confined to this
epitope; Abs to other epitopes on VP-3P and to other viral
proteins become generated in infected mice as rapidly
and efficiently as the neutralization Abs in LDV-C and
LDV-v infected mice (Cafruny et al., 1986; Plagemann et
al., 1995). These immune responses are associated with
the appearance in the spleen and lymph nodes of ger-
minal centers that contain large numbers of virions most
likely trapped by follicular dendritic cells (Plagemann et
al., 1995).
The epitope recognized by the neutralizing Abs elic-
ited in LDV-C and LDV-v infected mice seems to have
shifted slightly downstream since the binding of the Abs
to immobilized P5, though not inhibited by P7, P8, and
P13, is inhibited by the peptides that extend further
downstream, P9–P12, especially the LDV-C/v-specific P9
(Table 4). The Abs from LDV-C/LDV-v infected mice also
bind directly to P9, while poorly binding to P8 located
further upstream (Table 3). This epitope shift is probably
the result of amino acid substitutions associated with
changes in the hydrophobicity profile of the ectodomain
(Fig. 4).
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ectodomain in LDV virions plays an important role in the
ability of the virions to induce the generation of Abs that
neutralize LDV and bind to the epitope containing pep-
tides in ELISAs. The Abs generated in infected mice as
well as the neutralizing mAbs bound best to the full-
length ectodomain peptides (P3, P5, P6) and only poorly,
if at all, to most of the shorter truncated peptides (Table
3). This lack of binding to the shorter peptides seems to
have been due to a change in conformation or genera-
tion of steric hindrance during immobilization in the
ELISA wells since the same peptides in solution effi-
ciently blocked the binding of the Abs to the immobilized
full-length peptides (Table 4). Furthermore, it is clear that
the peptide binding Abs generated in mice infected with
the four different LDV quasispecies exhibit quasispecies-
specific differences in binding to the various peptides
(Tables 3 and 4), which must be due to amino acid
differences outside the epitope(s), most likely affecting
their conformation. In addition to the structure of the
VP-3P ectodomain per se, factors outside the ectodo-
main, such as perhaps its linkage to the M protein, can
also affect the conformation of the neutralizing epitopes,
since the peptide binding patterns of the Abs raised to
LDV-C and LDV-v differed slightly (Table 4), even though
the amino acid sequence of the VP-3P ectodomains of
the two LDVs is identical (Table 1).
The importance of epitope conformation was also in-
dicated by the failure of the BSA-conjugated full-length
peptides to induce Abs in mice that neutralized LDV,
even though the peptides were linked to BSA via the
same Cys residue that is thought to be involved in the
linkage of the VP-3P ectodomain to the ectodomain of
the M protein. The BSA–peptide conjugates induced high
levels of Abs that bound in the indirect ELISA to P3, P4,
and P5, but apparently to a denatured form of the neu-
tralization epitope, since they bound in an LDV quasi-
species-specific manner to the shorter peptides when
immobilized, but failed in solution to block the binding of
the Abs to immobilized P5. Thus only Abs to the native
form of the linear VP-3P ectodomain epitope possessed
neutralizing activity. This finding is of some interest in
relation to the use of peptides in antiviral vaccines. In the
case of another arterivirus, equine arteritis virus, vacci-
nation with a conjugate of keyhole limpet hemocyanin
and a peptide containing a neutralization epitope from
the ectodomain of the primary envelope glycoprotein
induced neutralizing Abs in horses but not in a rabbit
(Chirnside et al., 1995).
The conformation or nature of the neutralization
epitope also seems to be affected by various treatments
used to inactivate virions for vaccination since the pep-
tide binding patterns of the sets of neutralizing mAbs
generated to formalin-inactivated and UV-light-inacti-
vated LDV-P/LDV-vx differ slightly from that of the Abs
from LDV-P/LDV-vx infected mice and from each other
(Tables 3 and 4), but the nature of the alteration isunknown. Nevertheless, the binding of the mAbs to the
neutralization epitope correlates with their virion neutral-
ization ability (Li et al., 1998; Chen et al., 1999). In con-
trast, glutaraldehyde inactivation of virions appears to
destroy the epitope since the mAbs generated to glutar-
aldehyde-inactivated LDV-P/LDV-vx, though reacting with
VP-3P in immunoblots, failed to neutralize LDV-P/LDV-vx
(Harty et al., 1987) and to bind to P3 and P5 in the indirect
ELISA (data not shown).
The results are also of interest in that they detected
the generation of a second type of Ab that neutralizes
LDV in vitro. These Abs become generated in LDV-P/
LDV-vx as well as LDV-C/LDV-v infected mice, but only
beginning about 1 month p.i. and at low levels. These
Abs do not bind significantly to the peptides containing
the linear neutralizing epitope in the VP-3P ectodomain,
but instead are generated to another VP-3P epitope that
is weakly immunogenic and may also be recognized by
the rabbit neutralizing Abs (see above). The nature of this
epitope is unclear, but it is most likely discontinuous and
formed by the linkage of the VP-3P ectodomain to that of
the M protein. Abs to this epitope neutralize LDV-P/
LDV-vx and LDV-C/LDV-v in vitro to about the same ex-
tent (Chen et al., 2000), but only inefficiently requiring the
binding of many Ab molecules per virion (Cafruny et al.,
1986; Chen et al., 1999; Plagemann et al., 1992). These
Abs fail to affect LDV-P and LDV-vx replication in mice
(Fig. 5B), probably because they never attain a high
enough level in vivo to mediate efficient virion neutral-
ization. During the persistent phase of infection practi-
cally all virions are present in the circulation as infec-
tious Ab–virus complexes (Cafruny et al., 1986). Com-
bined, this virion sequestration by Abs and the blockage
of the linear neutralization epitope on the VP-3P ectodo-
main by N-glycans allow continuous cycles of cytopathic
replication of LDV-P and LDV-vx in a renewable subpopu-
lation of tissue macrophages that supports the lifelong
persistent infection. It seems likely that other viruses
have developed this type of mechanism to escape the
humoral immune response of the host.
MATERIALS AND METHODS
Mice
FVB mice were provided by the transgenic facilities of
the University of Minnesota. C57BL/6 mice were pur-
chased from The Jackson Laboratories. Plasma was ob-
tained from mice by the orbital bleeding method using
heparinized blood collection tubes (Fisher Scientific,
Pittsburgh, PA) as described previously (Chen and Plage-
mann, 1997).
LDVs
The common nonneuropathogenic LDV-P and LDV-vx
have been previously cloned by end-point dilution in
mice from the original LDV isolates LDV-PLA and LDV-
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19NEUTRALIZATION EPITOPE OF MOUSE LDVVIR, respectively, and the neuropathogenic laboratory
mutants LDV-C and LDV-v were similarly cloned from the
original neuropathogenic isolates LDV-C-BR and LDV-
VIR, respectively (Chen et al., 1998, 1999; Chen and
lagemann, 1997).
LDV concentrations were estimated by an end-point
ilution assay in FVB mice (Chen and Plagemann, 1997).
he assay is based on the 5- to 10-fold increase in
lasma lactate dehydrogenase activity invariably associ-
ted with an LDV infection (Plagemann, 1996; Plagemann
nd Moening, 1992). LDV titers are expressed as ID50.
LDV stocks consisted of plasma harvested from mice 1
day p.i. and contained 109 to 1010 ID50/ml. Mice were
infected by intraperitoneal injection of about 106 ID50.
Measurement of the binding of Abs to VP-3P peptides
by indirect ELISA
The procedure was as described previously (Li et al.,
1998). In brief, the wells of 96-well ELISA plates were
coated with synthetic peptides of various lengths repre-
senting the ectodomains of VP-3P of various cloned LDV
quasispecies (Table 1) in carbonate buffer, pH 9.6 (2
mg/well). The plates were then sequentially incubated
with blocking solution [1% (w/v) BSA and 0.25% (v/v)
Tween 20 in phosphate-buffered saline (PBS)], twofold
dilutions of various neutralizing mAbs (Table 2) or of
plasma from infected mice, alkaline phosphatase-conju-
gated goat anti-mouse IgG (Sigma Chemical Co., St.
Louis, MO), and enzyme substrate (Sigma 104). Between
each incubation with the next reagent the plates were
rinsed 3 or 4 times with 0.05% (v/v) Tween 20 in PBS
(PBS–Tween). The absorbance of the alkaline phospha-
tase reaction product was measured at 405 nm (A405)
ith an automatic microplate reader. The synthetic pep-
ides (Table 1) were synthesized and purified as previ-
usly described (Li et al., 1998) or synthesized and puri-
fied by the Microchemical Facility of the University of
Minnesota.
Measurement of inhibition of Ab binding to
immobilized P5 and P6 peptides by VP-3P ectodomain
peptides in solution
ELISA plates were coated with ORF 5 peptides P5 or
P6 (Table 1; 1 or 2 mg/well). The plates were rinsed twice
ith PBS–Tween and then incubated with blocking solu-
ion for 45 min at 37°C followed by incubation for 1.5 to
h at 37°C with mixtures of 50 ml of an Ab solution and
0 ml of twofold dilutions of VP-3P ectodomain peptides
(Table 1) in PBS generally from 20 or 10 to 0.6 or 0.3
mg/well. The plates were rinsed thrice with PBS–Tween,
sequentially incubated with alkaline phosphatase-conju-
gated anti-mouse IgG and substrate, and finally read at
405 nm as already described. The solutions of specific
Abs used in the test were the highest dilutions of Ab that
elicited maximum binding to immobilized peptides P3
and/or P5 as determined by indirect ELISA (see Figs. 1and 3). The Ab dilutions used are stated in the footnote
to Table 4.
Measurement of in vitro Ab neutralization of LDV
As described previously (Chen et al., 1999; Plagemann
et al., 1992), samples of LDV stocks were incubated in
vitro with undiluted normal mouse plasma (NMP) or
plasma from LDV infected mice (IMP). The residual LDV
infectivity in both samples was determined by titration in
mice. The degree of neutralization was defined as the
difference in titer between the LDV samples incubated
with NMP and IMP and was expressed in log10 ID50.
Immunization of FVB mice with peptides P3 and P5
Peptide–BSA conjugates were produced essentially
as described by Maloy et al. (1994). In brief, 1 ml of BSA
in 0.01 M phosphate buffer, pH 7.1 (10 mg/ml), was mixed
with 0.2 ml m-maleimidobenzoyl-N-hydroxysuccinimide
ester in dimethylformamide (10 mg/ml). The mixture was
incubated at room temperature for 30 min with stirring
and the activated BSA isolated by Sephadex G25 chro-
matography. After the pH of the eluate was adjusted to
7.0, 1.3 ml was mixed with 0.5 ml of 6 M guanidine
hydrochloride containing about 2 mg peptide P3 or P5
per milliliter. The mixtures were incubated at room tem-
perature for 3 h and then dialyzed at 4°C once against 2
liters dH2O overnight, twice against 2 liters dH2O for 3 h,
nd once against 2 liters PBS for 3 h. A sample of the
inal conjugate solution containing about 1.5 mg pro-
ein/ml was vigorously mixed with an equal volume of
FA and 0.2 ml of the mixture was injected intraperito-
eally into each of three mice. At 7 and 31 days later the
ice were reinoculated with a similar mixture of conju-
ate and IFA. Plasma was obtained 7 days after the last
njection and assayed for peptide binding activity. At this
ime individual mice immunized with P3–BSA or P5–BSA
nd a nonimmunized mouse were injected with 106 ID50
of LDV-C, LDV-v, or LDV-P. The mice were bled at inter-
vals thereafter and their plasma was analyzed for infec-
tious LDV and peptide binding Abs.
Reverse transcription-polymerase chain reaction
Total RNA was extracted from plasma of infected mice
and reverse transcribed and the cDNA was amplified by
PCR using LDV-P-, LDV-vx-, and LDV-C-specific primers
as described previously (Chen and Plagemann, 1997;
Chen et al., 1998, 1999).
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